Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Leveraging the species barrier to advance cancer therapy

Nature Genetics volume 45, pages 718–720 (2013)Cite this article

Subjects

The discovery of new therapeutic targets and the personalization of treatments are two active areas of cancer research. New studies suggest that a 'co-clinical' approach may expedite both therapeutic target validation and risk stratification in patients with advanced prostate cancer.

The pathway leading to the successful development of effective cancer therapeutics is steep and littered with hazards and obstacles. Yet, the destination is highly rewarding, with the promises of extended survival and improved quality of life for patients with cancer. Drug development in oncology requires the identification of key targets underlying tumor vulnerability and the investment of considerable resources to advance compounds through rigorous assessments of efficacy and tolerability. Because these steps are often time-consuming, approaches that can accelerate the process and expedite the identification of targets and agents with a very high likelihood of meaningful clinical impact are sorely needed.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Schematic of the cross-species approach for identifying and evaluating therapeutic targets.

References

  1. Lunardi, A. et al. Nat. Genet. 45, 747–755 (2013).

    Article  CAS  Google Scholar 

  2. Nardella, C., Lunardi, A., Patnaik, A., Cantley, L.C. & Pandolfi, P.P. Cancer Discov. 1, 108–116 (2011).

    Article  Google Scholar 

  3. Ryan, C.J. & Tindall, D.J. J. Clin. Oncol. 29, 3651–3658 (2011).

    Article  CAS  Google Scholar 

  4. Grasso, C.S. et al. Nature 487, 239–243 (2012).

    Article  CAS  Google Scholar 

  5. Barbieri, C.E. et al. Nat. Genet. 44, 685–689 (2012).

    Article  CAS  Google Scholar 

  6. Wang, S. et al. Cancer Cell 4, 209–221 (2003).

    Article  CAS  Google Scholar 

  7. Gao, H., Ouyang, X., Banach-Petrosky, W.A., Shen, M.M. & Abate-Shen, C. Cancer Res. 66, 7929–7933 (2006).

    Article  CAS  Google Scholar 

  8. Wang, G. et al. Nat. Genet. 45, 739–746 (2013).

    Article  CAS  Google Scholar 

  9. Kumari, R. et al. Carcinogenesis 33, 2076–2083 (2012).

    Article  CAS  Google Scholar 

  10. Beroukhim, R. et al. Nature 463, 899–905 (2010).

    Article  CAS  Google Scholar 

  11. Tomlins, S.A. et al. Science 310, 644–648 (2005).

    Article  CAS  Google Scholar 

  12. Chen, C.D. et al. Nat. Med. 10, 33–39 (2004).

    Article  Google Scholar 

  13. Sun, Y. et al. Nat. Med. 18, 1359–1368 (2012).

    Article  CAS  Google Scholar 

  14. Straussman, R. et al. Nature 487, 500–504 (2012).

    Article  CAS  Google Scholar 

  15. Shah, S.K. et al. J. Urol. 181, 621–626 (2009).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Song Zhao and Peter S. Nelson are in the Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.,

    Song Zhao & Peter S Nelson

Authors
  1. Song Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter S Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter S Nelson.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zhao, S., Nelson, P. Leveraging the species barrier to advance cancer therapy. Nat Genet 45, 718–720 (2013). https://doi.org/10.1038/ng.2683

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.2683

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer